Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain
- Conditions
- Ankle Sprain
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 206
- Registration Number
- NCT01255423
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
- Conditions
- Pain, Migraine
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 752
- Registration Number
- NCT01248468
A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy
- Conditions
- Primary Hypertension
- Interventions
- Drug: valsartan/amlodipine
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT01241487
- Locations
- 🇪🇬
Dr Ahmed Anwar Clinic,, Cairo, Egypt
Phase 4 Study in the Elderly Patients With T2DM
- Conditions
- ElderlyType 2 Diabetes Mellitus
- Interventions
- Drug: "Usual Care"
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 46
- Registration Number
- NCT01238978
- Locations
- 🇫🇷
Novartis Investigative Site, Versailles, France
🇫🇷Novartis Investigative Site #2, Venissieux, France
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- Drug: Aliskiren/Amlodipine 150/2.5 mgDrug: Aliskiren/amlodipine 150/5 mgDrug: Placebo of Aliskiren/amlodipine 150/2.5 mgDrug: Placebo of Aliskiren/amlodipine 150/5 mg
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1342
- Registration Number
- NCT01237223
- Locations
- 🇯🇵
Investigative Site, Tokyo, Japan
Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 317
- Registration Number
- NCT01233622
- Locations
- 🇨🇳
Novartis Investigative Site, Yongkang, Taiwan
🇷🇴Novartis Investigative Site #1, Oradea, Romania
🇷🇴Novartis Investigative Site #2, Oradea, Romania
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
- Conditions
- Typhoid Fever
- Interventions
- Biological: Vi-CRM197 vaccineBiological: Vi Polysaccharide (PS) vaccineBiological: Pneumococcal conjugate vaccine
- First Posted Date
- 2010-10-27
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT01229176
- Locations
- 🇮🇳
K.E.M. Hospital Research Centre, Pune, Maharastra, India
🇵🇰The Aga Khan University Hospital, Karachi, Pakistan
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
- Conditions
- Post-menopausal Osteoporosis
- Interventions
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 104
- Registration Number
- NCT01224717
- Locations
- 🇩🇪
Novartis Investigative Site, Munich, Germany
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 448
- Registration Number
- NCT01224366
- Locations
- 🇬🇧
Novartis Investigative Site, Carmarthen, United Kingdom
🇬🇧Novartis Investigative Site #1, Glasgow, United Kingdom
🇬🇧Novartis Investigative Site #2, Glasgow, United Kingdom
A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 498
- Registration Number
- NCT01220115
- Locations
- 🇺🇸
Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Oakland (CHO), Oakland, California, United States
🇺🇸Children's Hospital of Orange County Sickle Cell Disease Center, Orange, California, United States